-+ 0.00%
-+ 0.00%
-+ 0.00%

AtaiBeckley Completes Patient Dosing In Depression Drug Trial, Expects Depression Treatment Trial Data In Late 2026

Benzinga·07/06/2026 10:03:09
Listen to the news

AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD). The study randomized 156 patients, with topline data expected in Q4 2026.